Recent Scholarly Works
In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy Against Talaromyces marneffei.
Journal article J Fungi (Basel) · June 17, 2026 The dimorphic fungus Talaromyces marneffei causes talaromycosis, a life-threatening fungal disease with limited treatment options. Olorofim, a first-in-class orotomide antifungal that targets pyrimidine synthesis essential for fungal growth, has low minimu ... Full text Link to item CiteDevelopment and Clinical Evaluation of a Novel Talaromyces marneffei Mp1p Lateral Flow Assay for Rapid Diagnosis of Talaromycosis.
Journal article Clin Infect Dis · January 6, 2026 BACKGROUND: The diagnosis of talaromycosis, a life-threatening invasive fungal disease endemic in Southeast Asia, still relies on protracted culture methods. We report the development and clinical evaluation of a novel lateral flow assay (LFA) for the rapi ... Full text Link to item CiteIn vitro evidence to support amphotericin B and flucytosine combination therapy for talaromycosis.
Journal article PLoS Negl Trop Dis · December 2025 BACKGROUND: Talaromyces marneffei causes talaromycosis, a life-threatening fungal disease with limited treatment options. The standard treatment of amphotericin B (AmB) induction followed by itraconazole consolidation still results in 15% to 30% mortality. ... Full text Link to item CiteRecent Grants
Liposomal Amphotericin B and Flucytosine Antifungal Strategies for Talaromycosis (LAmB-FAST) - R01
ResearchResearch Associate · Awarded by National Institutes of Health · 2024 - 2031Development, Clinical Validation, and Readiness for Implementation of a Novel Mp1p D4 Point of Care Test for Rapid Diagnosis of Talaromycosis
ResearchResearch Associate · Awarded by National Institute of Allergy and Infectious Diseases · 2023 - 2028Tropical Medicine Research Center for Talaromycosis in Vietnam - U01
ResearchResearch Assistant · Awarded by National Institute of Allergy and Infectious Diseases · 2022 - 2027View All Grants